{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:50Z","timestamp":1786119350108,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1097\/ftd.0b013e3181cdc93e","type":"journal-article","created":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T05:34:48Z","timestamp":1268890488000},"page":"169-176","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Repercussions of Analytical Interferences Due to Aldosterone Antagonists in Digoxin Immunoassays: An Assessment"],"prefix":"10.1097","volume":"32","author":[{"given":"Ana","family":"Cobo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mart\u00edn-Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Victoria","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Dom\u00ednguez-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Mar Fern\u00e1ndez","family":"de Gatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210129","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0735-1097(02)01708-4","article-title":"Clinical benefits of low serum digoxin concentrations in heart failure.","volume":"39","author":"Adams","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R2-8-20210129","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jama.289.7.871","article-title":"Association of serum digoxin concentration and outcomes in patients with heart failure.","volume":"289","author":"Rathore","year":"2003","journal-title":"JAMA"},{"key":"R3-8-20210129","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2006.12.001","article-title":"Effects of digoxin at low serum digoxin concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial.","volume":"123","author":"Ahmed","year":"2008","journal-title":"Int J Cardiol"},{"key":"R4-8-20210129","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MAJ.0b013e318176b94d","article-title":"Digoxin: current use and approach to toxicity.","volume":"336","author":"Vivo","year":"2008","journal-title":"Am J Med Sci"},{"key":"R5-8-20210129","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00007691-199712000-00009","article-title":"Cross reactivity of TDX and OPUS immunoassay system for serum digoxin determination.","volume":"19","author":"Okazaki","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R6-8-20210129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/clinchem\/48.3.507","article-title":"Digoxin assays: frequent, substantial and potentially dangerous interference by spironolactone, canrenone and other steroids.","volume":"48","author":"Steimer","year":"2002","journal-title":"Clin Chem"},{"key":"R7-8-20210129","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jcla.10039","article-title":"Bidirectional (positive\/negative) interference of spironolactone, canrenone and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin.","volume":"16","author":"Dasgupta","year":"2002","journal-title":"J Clin Lab Anal"},{"key":"R8-8-20210129","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/FTD.0b013e31818b0e6a","article-title":"Effects of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.","volume":"30","author":"Dasgupta","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R9-8-20210129","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1001\/archinte.166.22.2539","article-title":"A method of determining the dose of digoxin for heart failure in the modern era.","volume":"166","author":"Bauman","year":"2006","journal-title":"Arch intern Med"},{"key":"R10-8-20210129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/clinchem\/33.3.387","article-title":"Desirable standards of performance for therapeutic drug monitoring.","volume":"33","author":"Fraser","year":"1987","journal-title":"Clin Chem"},{"key":"R11-8-20210129","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement.","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"R12-8-20210129","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1345\/aph.1L225","article-title":"Discordant results from real world patients samples assayed for digoxin.","volume":"42","author":"Jones","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R13-8-20210129","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00007691-199706000-00020","article-title":"Minimizing digoxin-like immunoreactivity with TDx digoxin in dialysis patients.","volume":"19","author":"Martin-Suarez","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R14-8-20210129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-198901000-00003","article-title":"Interaction between digoxin and propafenone.","volume":"11","author":"Calvo","year":"1989","journal-title":"Ther Drug Monit"},{"key":"R15-8-20210129","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/clinchem\/37.2.144","article-title":"Approaches to minimizing interference by cross-reacting molecules in immunoassays.","volume":"37","author":"Miller","year":"1991","journal-title":"Clin Chem"},{"key":"R16-8-20210129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1309\/3VNP-TWFQ-HT9A-1QH8","article-title":"Endogenous and exogenous digoxin-like immunoreactive substances. Impact on therapeutic drug monitoring of digoxin.","volume":"118","author":"Dasgupta","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"R17-8-20210129","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/00007691-200212000-00003","article-title":"Effect of analytical inaccuracy on dose adjustment for vancomycin, amikacin, and tobramycin using the Abbottbase Pharmacokinetics System.","volume":"24","author":"Zaera","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R18-8-20210129","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.ftd.0000243966.97964.11","article-title":"Pitfalls in TDM of antibiotic drug: analytical and modelling issues.","volume":"28","author":"Neef","year":"2006","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e3181cdc93e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:20:20Z","timestamp":1786040420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201004000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181cdc93e","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}